Author Topic: Drug Could Regrow Hair in Some with Hair Loss  (Read 541 times)

0 Members and 1 Guest are viewing this topic.

Offline Buster's Uncle

  • Geo's kind, I unwind, HE'S the
  • Planetary Overmind
  • *
  • Posts: 51337
  • €868
  • View Inventory
  • Send /Gift
  • Because there are times when people just need a cute puppy  Soft kitty, warm kitty, little ball of fur  A WONDERFUL concept, Unity - & a 1-way trip that cost 400 trillion & 40 yrs.  
  • AC2 is my instrument, my heart, as I play my song.
  • Planet tales writer Smilie Artist Custom Faction Modder AC2 Wiki contributor Downloads Contributor
    • View Profile
    • My Custom Factions
    • Awards
Drug Could Regrow Hair in Some with Hair Loss
« on: August 17, 2014, 11:49:07 pm »
Drug Could Regrow Hair in Some with Hair Loss
LiveScience.com
By Agata Blaszczak-Boxe, Contributing Writer  8 minutes ago



Most hair-loss drugs currently available may stop hair loss, but don't cause hair to regrow. Now, new research suggests that a drug already used to treat people with other conditions could restore hair growth in patients with one disease that can cause hair loss.

In a small new study, three people who took a drug called ruxolitinib daily for four to five months saw a complete regrowth of their hair. The patients had a condition called alopecia areata, which is an autoimmune disease that causes the loss of hair from the scalp or other areas of the body.

The drug used in the study is already approved by the Food and Drug Administration to treat people with myelofibrosis, a serious bone marrow disorder.

In the new study, the investigators also determined the cellular mechanism that causes hair loss in people with alopecia areata, which was not completely understood before.

"Additional clinical trials are needed to test the effectiveness of this drug in more patients in larger studies," said study author Angela M. Christiano, a professor of dermatology and genetics at Columbia University Medical Center in New York. "However, for patients with alopecia areata, this is an exciting result, because it offers a potential new class of drugs that have not been tried before in this disease, with some promising early results."

There is currently no approved treatment that can restore hair in patients with alopecia areata, which usually starts with the loss of small patches of hair on the scalp. In some cases, the condition can lead to the loss of all hair on the scalp or body.

Alopecia areata affects about 2 percent of the population, and about 6.5 million people in the United States have it, according to the National Alopecia Areata Foundation.  The course of the disease is highly unpredictable —patients' hair may grow back and fall out again at any point — and differs from one patient to another. People with alopecia often suffer psychologically and emotionally.

Researchers already knew that hair loss in people with alopecia occurs when cells of the immune system attack the base of the hair follicles. But until now, it was not clear which type of cell was responsible for this attack.

In the new study, the investigators found that a certain set of T cells are responsible for attacking hair follicles, and they also determined how those cells receive instructions to attack hair follicles. The investigators identified key immune pathways that could be targeted by drugs called JAK inhibitors.

Prior to the testing the drug on people with alopecia, the researchers tested two FDA-approved JAK inhibitors — ruxolitinib and tofacitinib— on mice with extensive hair loss from the disease, and found that the drugs effectively stopped the attack of T cells on hair follicles. Within 12 weeks of treatment, the drugs completely restored the mice's hair, and the hair remained for several months after stopping the treatment.

When the researchers tested ruxolitinib in the three people with the disease, they found that the attacking T cells disappeared from their scalps, and the patients regrew their hair.

"We believe this is a very exciting step forward for the treatment of alopecia areata," Christiano told Live Science. "We hope these findings will inspire future efforts to pursue the development of JAK inhibitors for this disease and represent a first rationally-selected treatment based on some exciting new scientific findings."

The researchers have not so far observed any adverse effects of ruxolitinib in their small trial, Christiano said. 

"In patients who do not have chronic illnesses and are otherwise healthy, the likelihood of side effects [from taking ruxolitinib] is smaller than in patients who have chronic illnesses," she said. "Side effects can include infection, and changes in certain blood tests such as a drop in platelets or anemia."

The new study was published online today (Aug. 17) in the journal Nature Medicine.


http://news.yahoo.com/drug-could-regrow-hair-hair-loss-221955737.html

 

* User

Welcome, Guest. Please login or register.
Did you miss your activation email?


Login with username, password and session length

Select language:

* Community poll

SMAC v.4 SMAX v.2 (or previous versions)
-=-
24 (7%)
XP Compatibility patch
-=-
9 (2%)
Gog version for Windows
-=-
106 (33%)
Scient (unofficial) patch
-=-
40 (12%)
Kyrub's latest patch
-=-
14 (4%)
Yitzi's latest patch
-=-
89 (28%)
AC for Mac
-=-
3 (0%)
AC for Linux
-=-
5 (1%)
Gog version for Mac
-=-
10 (3%)
No patch
-=-
16 (5%)
Total Members Voted: 316
AC2 Wiki Logo
-click pic for wik-

* Random quote

Fossils fuels in the last century reached their extreme prices because of their inherent utility: they pack a great deal of potential energy into an extremely efficient package. If we can but sidestep the 100-million-year production process, we can corner this market once again.
~CEO Nwabudike Morgan, Strategy Session

* Select your theme

*
Templates: 5: index (default), PortaMx/Mainindex (default), PortaMx/Frames (default), Display (default), GenericControls (default).
Sub templates: 8: init, html_above, body_above, portamx_above, main, portamx_below, body_below, html_below.
Language files: 4: index+Modifications.english (default), TopicRating/.english (default), PortaMx/PortaMx.english (default), OharaYTEmbed.english (default).
Style sheets: 0: .
Files included: 45 - 1228KB. (show)
Queries used: 36.

[Show Queries]